文献速递腹部CT

胃癌新辅助治疗反应的CT影像组学预测模型

Treatment-specific CT Radiomics Models To Predict Response To Neoadjuvant Therapy And Explore Individualized Treatment Selection In Gastric Cancer.
PubMed 文献 · Acad Radiol · 2026-07-13

回顾性研究纳入405例接受新辅助化疗或免疫化疗后行根治术的胃癌患者,基于门静脉期CT影像组学构建通用及治疗特异性模型。治疗特异性模型在验证集中AUC优于通用模型,双评分框架中接受模型推荐治疗者病理缓解率更高。

要点

  • 治疗特异性影像组学模型对胃癌新辅助治疗病理反应的预测效能优于通用模型
  • 双评分框架有助于个体化选择新辅助化疗或免疫化疗方案
  • 门静脉期CT影像组学特征可作为治疗前无创预测工具

核心结论

  • 治疗特异性影像组学模型在预测胃癌新辅助治疗病理反应方面优于通用模型
  • 双评分框架为个体化治疗方案选择提供了探索性方法

研究设计与样本

  • 回顾性研究共纳入405例接受新辅助化疗或新辅助免疫化疗后行根治性胃切除术的胃癌患者
  • 开发队列337例,时间验证队列68例,开发队列随机分为训练集235例和验证集102例
  • 影像组学特征提取自门静脉期CT图像,使用四种机器学习分类器构建模型

诊断标准与关键数值

  • 验证集中通用模型AUC为0.679,其中NAC亚组0.732,NAIC亚组0.659
  • 验证集中NAC特异性模型AUC为0.770,NAIC特异性模型AUC为0.753
  • 时间验证队列中NAIC特异性模型AUC为0.707,优于通用模型的0.626
  • 时间验证队列中NAC特异性模型AUC为0.563,通用模型为0.625,无优势
  • 双评分框架中NAC推荐组病理缓解率为46.4%对23.3%,P=0.043;NAIC推荐组为40.5%对19.4%,P<0.0001

临床应用与阅片要点

  • 治疗前门静脉期CT影像组学可辅助预测胃癌患者对新辅助治疗的病理反应
  • 根据拟用治疗方案选择对应的治疗特异性模型可能获得更准确的预测
  • 双评分框架可同时评估NAC和NAIC的反应概率,辅助个体化决策

局限性

  • 回顾性单中心研究设计
  • 时间验证队列样本量较小

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To develop and compare general and treatment-specific radiomics models based on pretreatment computed tomography (CT) for predicting pathological response to neoadjuvant therapy (NAT) in gastric cancer (GC), and to explore a dual-score framework for individualized treatment selection.

MATERIALS AND METHODS: This retrospective study included 405 patients with GC who underwent neoadjuvant chemotherapy (NAC) or neoadjuvant immunochemotherapy (NAIC) followed by radical gastrectomy, comprising 337 in the development cohort and 68 in a temporal test cohort. The development cohort was randomly divided into training (n = 235) and validation (n = 102) sets. Radiomics features were extracted from portal venous-phase CT images. Four machine learning classifiers were used to construct general and treatment-specific models. Treatment-specific models were cross-applied to generate paired NAC and NAIC response probabilities.

RESULTS: In validation, the general model achieved an AUC of 0.679 (NAC, 0.732; NAIC, 0.659), whereas the NAC-specific and NAIC-specific models achieved AUCs of 0.770 and 0.753. Repeated random-split analyses more frequently favored treatment-specific models. In the temporal test cohort, the NAIC-specific model outperformed the general model (AUC, 0.707 vs 0.626), whereas the NAC-specific model showed no advantage (AUC, 0.563 vs 0.625). In the dual-score framework, patients who received model-recommended treatment showed higher pathological response rates (NAC-recommended: 46.4% vs 23.3%, p = 0.043; NAIC-recommended: 40.5% vs 19.4%, p < 0.0001).

CONCLUSION: Treatment-specific radiomics models showed better discrimination than the general model for predicting pathological response to NAT in gastric cancer. The dual-score framework may provide an exploratory approach for individualized treatment selection.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Liu, Gao, Ma, et al. Treatment-specific CT Radiomics Models To Predict Response To Neoadjuvant Therapy And Explore Individualized Treatment Selection In Gastric Cancer. Acad Radiol. 2026. PMID: 42443011. doi:10.1016/j.acra.2026.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。